RxDoctor Payments Data

Amy Bick, NP

Primary Care · Atlanta, GANPI 1346690989

Payments from drug & device makers

$690in general payments, 2019–2025

Across 28 payments — averaging $24.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$189
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$107
  • Novartis$87
  • Boehringer Ingelheim$65
  • Daiichi Sankyo Inc.$43
  • Impulse Dynamics (USA) Inc.$32
  • plus $169 from 9 others

What the payments were for

  • Food & beverage$67698%
  • Education$142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$690 in reported general payments places this provider in the 55th percentile of 235 primary care providers in Georgia.

See all primary care providers in Georgia

Medicare billing

Part B allowed, 2024
$5,865
Medicare patients
59
Services billed
105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol21$29,103
EntrestoSacubitril/Valsartan21$28,498
JardianceEmpagliflozin18$18,814
Hydralazine Hcl22$433
Metoprolol Succinate27$397
Carvedilol35$322
Spironolactone38$154
Losartan Potassium25$129
Torsemide11$99
Furosemide18$72

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$14$29,10321 claims
NovartisEntresto$87$28,49821 claims
Boehringer IngelheimJardiance$65$18,81418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 235 primary care providers in Georgia.

Other primary care in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →